Mirum Pharmaceuticals, Inc. - common stock (MIRM)
MIRM moved a median of -0.11% 30 minutes after news, and +0.25% by the close. How MIRM actually reacts to news — the realized, point-in-time move the market made, measured across 437 labeled events over the last three years with zero look-ahead.
MIRM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.08% | 42% | 435 |
| 30-min | -0.11% | 45% | 435 |
| 60-min | -0.07% | 48% | 435 |
| to close | +0.25% | 55% | 435 |
| Middle 50% of MIRM reactions | -1.13% to +0.93% |
|---|---|
| Median reaction (30-min) | -0.11% |
| Measured reactions | 437 |
Half of all Mirum Pharmaceuticals, Inc. - common stock news events land between -1.13% and +0.93% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MIRM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.46% | 60% | -0.35% |
| Coverage initiations | 25 | -0.24% | 32% | -0.41% |
| Rating reiterations | 145 | +0.14% | 56% | +0.14% |
| Price-target raises | 39 | +0.40% | 59% | +0.37% |
| Price-target cuts | 11 | 0.00% | 46% | -0.39% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how MIRM ranks against every other measured name →
That’s how MIRM usually reacts — get an email when it moves on news →Email me when MIRM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MIRM's baseline. Nothing else.
Recent MIRM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.94% | -2.84% | |
| Form 8-K Mirum Pharmaceuticals, For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | -7.48% | |
| Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases | Press release | Business Wire | -0.25% | -1.33% | |
| Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases | Press release | Business Wire | -0.25% | -1.33% | |
| Form 8-K Mirum Pharmaceuticals, For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -1.01% | -2.27% | |
| Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus | Press release | Business Wire | -1.01% | -2.27% | |
| Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 | Press release | Business Wire | -1.01% | -2.27% | |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.82% | -3.76% | |
| Form 8-K Mirum Pharmaceuticals, For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | +1.06% | |
| Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer | Press release | Business Wire | +0.23% | +1.06% | |
| Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | -1.22% | -0.92% | |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.29% | +0.68% | |
| Form 10-Q Mirum Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.29% | +4.28% | |
| Form 8-K Mirum Pharmaceuticals, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | +4.28% | |
| Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | +1.29% | +4.28% | |
| Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 | Press release | Business Wire | +0.04% | +4.21% | |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.23% | +0.98% | |
| Form 8-K Mirum Pharmaceuticals, For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +0.68% | -0.99% | |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.48% | -0.52% | |
| Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 | Press release | Business Wire | -0.95% | -3.67% | |
| Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 | Press release | Business Wire | -0.09% | +3.84% | |
| Form 8-K Mirum Pharmaceuticals, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.67% | +0.61% | |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.03% | -6.66% | |
| Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering | Press release | Business Wire | +2.34% | +1.07% | |
| Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes | Press release | Business Wire | +2.34% | +1.07% | |
| Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.16% | -0.08% | |
| Form 10-Q Mirum Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.51% | -6.50% | |
| Form 8-K Mirum Pharmaceuticals, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -4.51% | -6.50% | |
| Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | -4.51% | -6.50% | |
| Form 8-K Mirum Pharmaceuticals, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +10.71% | +18.20% | |
| Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis | Press release | Business Wire | +10.71% | +18.20% | |
| Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 | Press release | Business Wire | +10.71% | +18.20% | |
| Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 | Press release | Business Wire | +0.13% | +1.83% | |
| Form 8-K Mirum Pharmaceuticals, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | +0.52% | |
| Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus | Press release | Business Wire | +0.90% | +0.52% | |
| Form ARS Mirum Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.14% | +0.86% | |
| Form DEF 14A Mirum Pharmaceuticals, For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -1.46% | -1.09% | |
| Form DEFA14A Mirum Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -1.46% | -1.09% | |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.08% | +0.68% | |
| Form 8-K/A Mirum Pharmaceuticals, For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | +1.36% | |
| Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases | Press release | Business Wire | +0.59% | +2.07% | |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +2.70% | +0.59% | |
| Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus | Press release | Business Wire | +0.04% | -5.10% | |
| Form 10-K Mirum Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.55% | -4.50% | |
| Form 8-K Mirum Pharmaceuticals, For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | -4.50% | |
| Form S-3ASR Mirum Pharmaceuticals, | SEC filing · Form S-3ASR | SEC EDGAR | -0.55% | -4.50% | |
| Form S-8 Mirum Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -0.55% | -4.50% | |
| Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update | Press release | Business Wire | -0.55% | -4.50% | |
| Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.23% | +0.69% | |
| Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 | Press release | Business Wire | +0.09% | +0.52% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MIRM section they belong to.
Where else MIRM is measured.
MIRM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Mirum Pharmaceuticals, Inc. - common stock's median reaction calculated?
Every labeled MIRM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 437 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of MIRM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MIRM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.